NO307447B1 - Anvendelse av et pregnanderivat - Google Patents

Anvendelse av et pregnanderivat

Info

Publication number
NO307447B1
NO307447B1 NO940777A NO940777A NO307447B1 NO 307447 B1 NO307447 B1 NO 307447B1 NO 940777 A NO940777 A NO 940777A NO 940777 A NO940777 A NO 940777A NO 307447 B1 NO307447 B1 NO 307447B1
Authority
NO
Norway
Prior art keywords
derivative
pregnancy
alpha
pregnane
oacyl
Prior art date
Application number
NO940777A
Other languages
English (en)
Other versions
NO940777D0 (no
NO940777L (no
Inventor
Godefridus Hermanus Jo Deckers
Helenius Jan Kloosterboer
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of NO940777D0 publication Critical patent/NO940777D0/no
Publication of NO940777L publication Critical patent/NO940777L/no
Publication of NO307447B1 publication Critical patent/NO307447B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Fats And Perfumes (AREA)
NO940777A 1993-03-05 1994-03-04 Anvendelse av et pregnanderivat NO307447B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93200631 1993-03-05

Publications (3)

Publication Number Publication Date
NO940777D0 NO940777D0 (no) 1994-03-04
NO940777L NO940777L (no) 1994-09-06
NO307447B1 true NO307447B1 (no) 2000-04-10

Family

ID=8213673

Family Applications (1)

Application Number Title Priority Date Filing Date
NO940777A NO307447B1 (no) 1993-03-05 1994-03-04 Anvendelse av et pregnanderivat

Country Status (14)

Country Link
US (1) US5512556A (no)
EP (1) EP0613687B1 (no)
JP (1) JP3391539B2 (no)
KR (1) KR100312061B1 (no)
AT (1) ATE180669T1 (no)
AU (1) AU671706B2 (no)
CA (1) CA2116829C (no)
DE (1) DE69418744T2 (no)
DK (1) DK0613687T3 (no)
ES (1) ES2134313T3 (no)
GR (1) GR3031114T3 (no)
NO (1) NO307447B1 (no)
NZ (1) NZ260017A (no)
ZA (1) ZA941464B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196079T3 (es) * 1994-09-22 2003-12-16 Akzo Nobel Nv Procedimiento de fabricacion de unidades posologicas por medio de una granulacion por via humeda.
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable
IL141850A (en) * 1998-10-16 2005-11-20 Akzo Nobel Nv High purity composition comprising (7alpha,17alpha)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-3n-20-yn-3-one
EP1212345B1 (en) * 1999-04-06 2003-08-06 Akzo Nobel N.V. Orally active 7-alpha-alkyl androgens
TR200200575T2 (tr) * 1999-09-06 2002-06-21 Akzo Nobel N. V. 11 Konumunda bir hidrokarbon ikame ediciye sahip, aromatik olmayan östrojenik steroidler.
BR0112791A (pt) 2000-07-28 2003-06-24 Akzo Nobel Nv Composto esteroidal 16alfa-substituido, uso do mesmo, métodos de tratamento para ativação seletiva de receptores de estrogênio do subtipo alfa, e para terapia de reposição hormonal ou contracepção, e, composição farmacêutica
GB0125061D0 (en) * 2001-10-18 2001-12-12 Norton Healthcare Ltd Pharmaceutical composition
EP1444247B1 (en) * 2001-10-18 2007-06-13 Norton Healthcare Limited Tibolone formulations
PL371181A1 (en) * 2002-01-22 2005-06-13 Akzo Nobel N.V. Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
US20060051420A1 (en) * 2002-11-20 2006-03-09 Pieter De Haan Pharmaceutical tablets containing tibolone and a coating
UA89964C2 (ru) 2004-09-08 2010-03-25 Н.В. Органон 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
CN116987680A (zh) * 2022-04-25 2023-11-03 复旦大学 支链氨基酸转氨酶1的功能获得性突变体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4701450A (en) * 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
FR2706454B1 (fr) * 1993-06-17 1995-09-15 Roussel Uclaf Nouveaux 19-Nor stéroïdes, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
KR940021064A (ko) 1994-10-17
NO940777D0 (no) 1994-03-04
EP0613687A1 (en) 1994-09-07
NO940777L (no) 1994-09-06
ES2134313T3 (es) 1999-10-01
ATE180669T1 (de) 1999-06-15
AU671706B2 (en) 1996-09-05
CA2116829A1 (en) 1994-09-06
EP0613687B1 (en) 1999-06-02
KR100312061B1 (ko) 2001-12-28
US5512556A (en) 1996-04-30
AU5754294A (en) 1994-09-08
JP3391539B2 (ja) 2003-03-31
JPH072673A (ja) 1995-01-06
DE69418744T2 (de) 1999-11-11
NZ260017A (en) 1997-06-24
CA2116829C (en) 2004-09-14
DE69418744D1 (de) 1999-07-08
ZA941464B (en) 1994-09-27
GR3031114T3 (en) 1999-12-31
DK0613687T3 (da) 1999-12-06

Similar Documents

Publication Publication Date Title
RU2088589C1 (en) Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4
IL136044A (en) 2-aminoacetamide derivatives and pharmaceutical compositions containing the same
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
AU7815791A (en) Heterocyclene derivatives
HU9600834D0 (en) Quinazoline derivatives
IL175398A0 (en) Steroidal compounds and pharmaceutical compositions containing them for treating oxidative stress and inflammation
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
NO940777D0 (no) Anvendelse av et pregnanderivat
DK0694545T3 (da) Substituerede dibenzoxazepinforbindelser, farmaceutiske sammensætninger og anvendelsesmetoder
MD1560G2 (ro) Compuşi ciclici, compoziţii farmaceutice pe baza lor şi metode de tratament al infecţiilor sau bolilor provocate de retrovirusuri
TW223016B (no)
MY114282A (en) Anthracycline derivatives
GB9302046D0 (en) Antiumoral compound-v
HU9400908D0 (en) Pharmaceutical compositions for treatng skin disorders
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
DE69528984T2 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
TH15815A (th) การใช้อนุพันธ์เพรคเนม
DE3882956D1 (de) Gegen die zerebrale insuffizienz wirksame verbindungen.
KR910000786A (ko) 콜레스타디엔 유도체, 이의 제조방법 및 HMG-CoA 환원제를 저해하는 작용을 하는 약제로서의 이의 용도
HK1007857A1 (en) New compound leustroducsin H its preparation and its therapeutic use
TH10441B (th) การใช้อนุพันธ์เพรคเนม